2-Arachidonoyl Glycerol (2-AG) Cannabinoid Research

2-Arachidonoyl Glycerol (2-AG) Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Clinical Meta-analyses


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 457 studies associated with 2-Arachidonoyl Glycerol (2-AG).

Here is a small sampling of 2-Arachidonoyl Glycerol (2-AG) studies by title:

Components of the 2-Arachidonoyl Glycerol (2-AG) Research Dashboard

  • Top medical conditions associated with 2-Arachidonoyl Glycerol (2-AG)
  • Proven effects in clinical trials for 2-Arachidonoyl Glycerol (2-AG)
  • Receptors associated with 2-Arachidonoyl Glycerol (2-AG)
  • Individual study details for 2-Arachidonoyl Glycerol (2-AG)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - 2-Arachidonoyl Glycerol (2-AG)

Description of 2-Arachidonoyl Glycerol (2-AG)

Raphaeal Mechoulam's et al., from the Hebrew University, Israel and T. Sugiura et al., from Teikyo University, Japan described the discovery of a second endogenous cannabinoid subsequently named 2-arachidonoylglycerol (2-AG) in 1994-1995.

2-AG is an ester formed from the essential fatty acid omega-6-arachidonic acid and glycerol.

Monoacylglycerol lipase (MAGL) is a key enzyme that metabolizes 2-AG.

Other Names:

2-Arachidonoyl Glycerol

2-Arachidonylglycerol, 2-arachidonoylglycerol, 2-Arachidonoyl Glycerol (and numerous others)

IUPAC Name: 1,3-dihydroxypropan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate

Molecular Formula: C23H38O4


2-Arachidonoyl Glycerol (2-AG) Properties and Effects

The Endocannabinoid System (ECS) and 2-AG:

  • 2-AG release plays a role in the rewarding consequences of sexual arousal and orgasm (J. Fuss et al., 2017)

The Endocannabinoidome (eCBome) and 2-AG:

2-Arachidonoyl Glycerol (2-AG) Receptor Binding

Endocannabinoid System (ECS):

Ki legend:

  • Full/strong agonist Ki ~1-9nM

  • Moderate agonist Ki ~10-99nM

  • Weak agonist Ki ~100-999nM

  • Very weak agonist Ki ~1,000-up nM

(The reader is reminded that a smaller Ki is associated with the strongest effects.)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.